{"id":"sodium-ferric-gluconate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Chest pain"},{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1201494","moleculeType":"Unknown"},"_dailymed":{"setId":"1fe028ff-42ac-4329-b1a5-a9dadfcb79f6","title":"FERRLECIT (SODIUM FERRIC GLUCONATE COMPLEX) INJECTION [SANOFI-AVENTIS U.S. LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of ferric iron bound to gluconate, which allows for intravenous administration and cellular uptake of iron. Once administered, the iron is released and incorporated into hemoglobin and other iron-dependent proteins, restoring oxygen-carrying capacity and correcting iron deficiency anemia. This formulation is designed to minimize adverse effects associated with free iron while maintaining bioavailability.","oneSentence":"Sodium ferric gluconate is an iron replacement therapy that delivers ferric iron in a stable gluconate complex to replenish depleted iron stores.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:47.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease on hemodialysis"},{"name":"Iron deficiency anemia in non-dialysis chronic kidney disease patients"}]},"trialDetails":[{"nctId":"NCT06248749","phase":"PHASE3","title":"Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2024-02-29","conditions":"Anaemia in Ovarian Carcinoma","enrollment":200},{"nctId":"NCT04063033","phase":"PHASE4","title":"IV Iron in Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2019-09-01","conditions":"Heart Failure","enrollment":34},{"nctId":"NCT04797832","phase":"PHASE4","title":"IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2020-10-18","conditions":"Iron Deficiency Anemia Due to Blood Loss, Aortic Stenosis","enrollment":200},{"nctId":"NCT02399449","phase":"PHASE4","title":"IV Iron Safety: Evaluation of Iron Species in Healthy Subjects","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-09-15","conditions":"Anemia","enrollment":110},{"nctId":"NCT01414075","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-07-21","conditions":"Dialysis, Anemia","enrollment":60},{"nctId":"NCT00223938","phase":"PHASE4","title":"Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.","status":"TERMINATED","sponsor":"Sanofi","startDate":"2003-12-30","conditions":"Anemia","enrollment":112},{"nctId":"NCT04587141","phase":"PHASE3","title":"Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2020-01-01","conditions":"Iron Deficiency Anemia, Inflammatory Bowel Diseases","enrollment":300},{"nctId":"NCT02817555","phase":"PHASE4","title":"Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Andrea L Woodland","startDate":"2010-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":50},{"nctId":"NCT03771092","phase":"NA","title":"Comparing the Efficacy of Different Iron Formulations: Sucrosomal Ferric Pyrophosphate, SunActive®Fe and Intravenous Ferric Gluconate","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2015-11-02","conditions":"Iron Deficiency Anemia","enrollment":148},{"nctId":"NCT00481624","phase":"PHASE2","title":"Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2007-05","conditions":"Anemia","enrollment":""},{"nctId":"NCT00704353","phase":"PHASE3","title":"Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2008-06","conditions":"Anemia","enrollment":735},{"nctId":"NCT00224081","phase":"PHASE4","title":"DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-09","conditions":"Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis","enrollment":134},{"nctId":"NCT01925703","phase":"PHASE4","title":"Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-04","conditions":"Heart Failure, Iron Deficiency Anemia","enrollment":13},{"nctId":"NCT02312414","phase":"NA","title":"Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype","status":"UNKNOWN","sponsor":"The Nazareth Hospital, Israel","startDate":"2014-10","conditions":"Anemia","enrollment":25},{"nctId":"NCT00223977","phase":"PHASE2, PHASE3","title":"2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-12","conditions":"Iron Deficiency Anemia","enrollment":146},{"nctId":"NCT00560976","phase":"NA","title":"Serum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2005-12","conditions":"Renal Failure Chronic Requiring Hemodialysis","enrollment":100},{"nctId":"NCT00223964","phase":"PHASE4","title":"Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-06","conditions":"Anemia","enrollment":59},{"nctId":"NCT00354692","phase":"PHASE4","title":"Effect of Two Iron Preparations on Protein in the Urine","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2006-06","conditions":"Kidney Failure, Chronic, Anemia, Iron-Deficiency","enrollment":12},{"nctId":"NCT00224055","phase":"PHASE4","title":"Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia, Iron-Deficiency, Kidney Failure, Chronic","enrollment":89},{"nctId":"NCT00224042","phase":"PHASE4","title":"Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia, Iron-Deficiency, Kidney Failure, Chronic","enrollment":52},{"nctId":"NCT00224068","phase":"PHASE4","title":"Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2002-05","conditions":"Anemia","enrollment":180},{"nctId":"NCT00534144","phase":"PHASE1","title":"Comparison Between Effects of Two Iron Preparations on Protein in the Urine","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2007-09","conditions":"Kidney Failure, Chronic, Anemia, Iron-Deficiency","enrollment":74},{"nctId":"NCT00661999","phase":"PHASE3","title":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":502},{"nctId":"NCT00224003","phase":"PHASE4","title":"Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia","enrollment":23}],"_emaApprovals":[],"_faersSignals":[{"count":240,"reaction":"VOMITING"},{"count":237,"reaction":"NAUSEA"},{"count":233,"reaction":"ABDOMINAL DISTENSION"},{"count":232,"reaction":"ABDOMINAL PAIN"},{"count":227,"reaction":"APPENDICITIS"},{"count":227,"reaction":"ASCITES"},{"count":227,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"},{"count":227,"reaction":"SEPSIS"},{"count":224,"reaction":"APPENDICOLITH"},{"count":222,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"}],"_approvalHistory":[],"publicationCount":120,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ferrlecit"],"phase":"marketed","status":"active","brandName":"Sodium ferric gluconate","genericName":"Sodium ferric gluconate","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium ferric gluconate is an iron replacement therapy that delivers ferric iron in a stable gluconate complex to replenish depleted iron stores. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in non-dialysis chronic kidney disease patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}